Reports / Specific Analyses

Dear colleagues,

The 1996-2019 update of the Nationwide Registry for Childhood Hematological Malignancies (NARECHEM-ST, www.narechem.gr) in Greece is available. Updated data have been also contributed to the IARC related European Pediatric Cancer Registries (ACCIS, CI5-X CI5plus, EUROCIM και EUROCAR) as well as to interested scientists under certain terms and conditions and following a request addressed to E. Petridou and E. Ntzani.

Reports

  1. Childhood leukemia in Greece (1996-2019): ACUTE LEUKEMIA (ALL & AML)
    · Annual Crude and Age-Standardized Incidence Rates per 1,000,000
    · Annual Age-Standardized Incidence Rates (AIR) per 1,000,000 by histological subtype
    · Age-Standardized Incidence Rates (AIR) per 1,000,000 by histological subtype and gender
    · Incidence Rates per 1,000,000 by age group and gender
    · Incidence Rates per 1,000,000 by age group and histological subtype

  2. Childhood lymphoma in Greece (1996-2019): LYMPHOMA (HL and NHL)
    · Annual Crude and Age-Standardized Incidence Rates per 1,000,000
    · Annual Age-Standardized Incidence Rates (AIR) per 1,000,000 by histological subtype
    · Annual Age-Standardized Incidence Rates (AIR) per 1,000,000 by histological subtype
    · Age-Standardized Incidence Rates (AIR) per 1,000,000 by histological subtype and gender
    · Incidence Rates per 1,000,000 by age group and histological subtype
    · Incidence Rates per 1,000,000 by age group and gender

  3. Childhood central nervous system (CNS) tumors (2010-2019)
    · Incidence Rates per 1,000,000 by age group and histological subtype
    · Annual Crude and Age-Standardized Incidence Rates per 1,000,000
    · Number of cases by behavior
    · Incidence Rates per 1,000,000 by age group and gender
    · Age-Standardized Incidence Rates (AIR) per 1,000,000 by behavior and gender
    · Annual Age-Standardized Incidence Rates (AIR) per 1,000,000 by behavior
    · Number of cases by ICCC-3 group III histological subtype
    · Number of cases by histological subtype
    · Incidence Rates per 1,000,000 by age group and ICCC-3 group III histological subtype
    · Incidence Rates per 1,000,000 by age group and histological subtype
    · Age-Standardized Incidence Rates (AIR) per 1,000,000 by gender and ICCC-3 group III histological subtype
    · Age-Standardized Incidence Rates (AIR) per 1,000,000 by histological subtype and gender

  4. Childhood Neuroblastomas in Greece (2009-2019)
    · Percentage of cases by stage of INRG
    · Annual Crude and Age-Standardized Incidence Rates per 1,000,000
    · Incidence Rates per 1,000,000 by age group and gender
    · Annual Crude Incidence Rates (CIR) per 1,000,000 by age group
    · Annual Age-Standardized Incidence Rates (AIR) per 1,000,000 by gender

  5. Childhood Wilm’s Tumors (Nephroblastomas) in Greece (2009-2019)
    · Percentage of cases by anatomical stage
    · Annual Crude and Age-Standardized Incidence Rates per 1,000,000
    · Incidence Rates per 1,000,000 by age group and gender
    · Annual Crude and Age-Standardized Incidence Rates per 1,000,000
    · Incidence Rates per 1,000,000 by age group and gender
    · Annual Crude Incidence Rates (CIR) per 1,000,000 by age group
    · Annual Age-Standardized Incidence Rates (AIR) per 1,000,000 by gender

  6. Childhood Liver Tumors in Greece (2001-2019)
    · Annual Crude and Age-Standardized Incidence Rates per 1,000,000
    · Annual Age-Standardized Incidence Rates (AIR) per 1,000,000 by gender
    · Annual Crude Incidence Rates (CIR) per 1,000,000 by age group
    · Incidence Rates per 1,000,000 by age group and gender


NARECHEM-ST descriptives at a glance:

    LEUKEMIA
  • Time trends (1996-2019) of childhood leukemias in Greece reach the statistically significant increase observed in other developed countries only with regards the crude incidence rate and merely so regarding the age standardized one
  • ALL and AML leukemia subtypes both contribute to the annual incidence increase, though the trend does not reach statistical significance in either of them, possibly due to small numbers
  • Gender and age patterns are in line with literature, Specifically, boys outnumber girls (male/female incidence rate ratio: 1.18) on account of ALL preponderance (male/female incidence rate ratio: 1.23), whereas the gender ratio for AML is 0.85
  • The peak age distribution for ALL is 1-4 years, whereas AML is more prevalent among less than two years infants and adolescents
  • LYMPHOMA
  • Time trends (1996-2021) show no increasing trends, but rather fluctuations expected during the study period. Non Hodgkin outnumber Hodgkin lymphomas (1.35), whereas Burkitt Non Hodgkin lymphomas comprise 46% of total Burkitt lymphomas
  • Overall, boys outnumber girls by 2.3; the gender ratio is 3:1 for Non Hodgkin and 3:2 for Hodgkin lymphoma
  • Lymphomas are rare in early childhood (0-4 years:14.2%) their proportion increases to 33.1% among children 5-9 years and peak among those 10-14 year of age (52.7%)
  • CNS tumors
  • Time trends (2010-2019) of CNS tumors during the study period remained relatively constant. Of the total CNS tumors during the study period, 59% had malignant behavior. Incidence rates of CNS tumors seem to decrease by age group.
  • The majority of CNS tumors regarded astrocytomas (37%), followed by embryonal tumors (22%), ependynomas (10%) and other giliomas (9%).
  • WILM'S tumors
  • Time trends of Wilm’s tumors showed a non-significant decrease of-4.23% (95% CI: -9.33%, 1.16%) during the study period (2009-2019).
  • The majority of Wilm’s tumors (86.5%) had an anatomical stage I-III, while the incidence rates peak within the age group of 1-4 years.
  • NEUROBLASTOMA
  • Time trends of neuroblastomas showed a non-significant decrease of- 2.42% (95% CI: -6.47%, 1.79%) during the study period (2009-2019). Incidence rates are higher during the first year of life and higher for boys compared to girls.
  • Based on the INRG stages, most neuroblastomas were L1 stage (33.5%) followed by M stage (32%).
  • LIVER tumors
  • No significant time trend was observed for liver tumors during the study period (2001-2019).
  • The vast majority of cases are observed during the first year of life, although the rates seem to increase for the age group of 1-4 years during the study period.

    • The NARECHEM-ST Τeam:
      Medical Director - Principal Investigator: Prof. Eleni Petridou MD, PhD
      Data Manager - Analyst & Co-Principal Investigator: Associate Prof. Evangelia Ntzani MD, PhD
      Clinical Data Collection Manager: Prof. Theodora Psaltopoulou MD, PhD
      Biosample Manager: Asst. Prof. Maria Kantzanou MD, PhD
      Registry and Clinical Data Manager: Nick Dessypris, Statistician (1996-2019), George Markozannes, Biostatistician (since 2020)
      Field coordinator and interviewers: E. Bouka, P. Bouka
      Administrator: A. Alexopoulos